Ascletis Pharma announced new data presentations at the 33rd European Congress on Obesity, highlighting their obesity drug candidates. ASC47 combined with semaglutide showed up to 111.8% greater weight loss compared to semaglutide alone. ASC36 demonstrated a much longer half-life and superior weight loss effects in preclinical models compared to existing treatments. These advancements suggest potential new effective therapies for obesity management, with further clinical development anticipated.
Aduro Clean Technologies Inc., a cleantech company specializing in converting low-quality materials into valuable resources, has received final approval to list its common shares on the Toronto Stock Exchange (TSX) under the ticker "ACT" starting May...
Aduro Clean Technologies, a clean tech company specializing in chemical recycling of low-value raw materials, has received final approval to list its common shares on the Toronto Stock Exchange (TSX) under the symbol ACT starting May 27, 2026. Concur...
The 2026 China (Jinhua Mountain) International Camping Congress was held from May 16-17 in Zhejiang Province, focusing on integrating culture, sports, tourism, and industry to develop camping tourism and leisure. The event attracted around 200 guests...
The Schall Law Firm is investigating UP Fintech Holding Limited for possible securities law violations after a Reuters report revealed China's crackdown on illegal cross-border securities trading. The report accused UP Fintech's Tiger subsidiary of o...
Trillion Energy International has filed its audited financial statements for 2025 and applied to lift its management cease trade order. The company is shifting focus to onshore oil exploration in southeastern Türkiye, holding a 29% interest in the M4...
